Top Analyst Reports For Visa, GE, GlaxoSmithKline & Others
Zacks Investment Research | May 26, 2017 12:44AM ET
Friday May 26, 2017
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), General Electric Company (NYSE:GE) and GlaxoSmithKline plc (GSK). You can see >>>
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst likes the improving coal scenario, which is aiding overall volumes at CSX. The company's efforts to check costs & reward shareholders also raise optimism.
Medtronic delivered another stellar quarter on balanced segmental performance. Per the Zacks analyst, innovations, acquisition and synergy are the growth drivers.
Per the Zacks analyst, strong demand for the company's 4G LTE products and its current restructuring initiatives will be growth drivers.
Strong portfolio, focus on non-gaming activities, improving economy and tourism in Las Vegas should drive growth. Despite Macau revival, sustainability of revenues from the VIP market is a concern.
Per the Zacks analyst, continued benefits of AIG's capital return, expense reductions, improved underwriting will lead to higher ROE; soft commercial business, exposure to catastrophe bothers.
Per the Zacks Analyst, Deere will gain from improving dairy market and political scenario in Brazil.
The Zacks analyst believes Devon Energy (NYSE:DVN)'s cost cutting initiatives, systematic investments and improving commodity prices will help it to boost its performance amid rising competition.
The Zacks analyst likes the improving coal scenario, which is aiding overall volumes at CSX. The company's efforts to check costs & reward shareholders also raise optimism.
Medtronic delivered another stellar quarter on balanced segmental performance. Per the Zacks analyst, innovations, acquisition and synergy are the growth drivers.
Per the Zacks analyst, strong demand for the company's 4G LTE products and its current restructuring initiatives will be growth drivers.
Strong portfolio, focus on non-gaming activities, improving economy and tourism in Las Vegas should drive growth. Despite Macau revival, sustainability of revenues from the VIP market is a concern.
Per the Zacks analyst, continued benefits of AIG's capital return, expense reductions, improved underwriting will lead to higher ROE; soft commercial business, exposure to catastrophe bothers.
Per the Zacks Analyst, Deere will gain from improving dairy market and political scenario in Brazil.
The Zacks analyst believes Devon Energy (NYSE:DVN)'s cost cutting initiatives, systematic investments and improving commodity prices will help it to boost its performance amid rising competition.
New Upgrades/h6
The Zacks analyst says Merck's new drugs Keytruda and Zepatier should drive sales. In-fact, Keytruda's uptake in first line lung cancer and potential label expansion are catalysts for the stock in 2017.
The Zacks analyst believes that Morgan Stanley's initiatives to control cost should continue to support bottom line growth. Also, the company's efforts to improve revenues are impressive.
Per the Zacks Analyst, Abbott's ongoing integration and synergy achievement of St Jude is quite encouraging. Also the company's recent product launch and CE mark for devices pulled up its share price.
The Zacks analyst says Merck's new drugs Keytruda and Zepatier should drive sales. In-fact, Keytruda's uptake in first line lung cancer and potential label expansion are catalysts for the stock in 2017.
The Zacks analyst believes that Morgan Stanley's initiatives to control cost should continue to support bottom line growth. Also, the company's efforts to improve revenues are impressive.
Per the Zacks Analyst, Abbott's ongoing integration and synergy achievement of St Jude is quite encouraging. Also the company's recent product launch and CE mark for devices pulled up its share price.
New Downgrades/h6
Per the Zacks analyst, Mylan will remain under pressure as EpiPen sales decline due to competition and entry of generics. The CRL for generic Advair was also a huge setback given the market potential.
According to the Zacks analyst, CSRA's forecast of lower new business revenues as well as lower win rate will significantly hurt top-line growth in fiscal 2018.
Seasonality in demand and fast increasing R&D expenses at the Commercial Networks segment, in relation to ViaSat-3 payloads, are expected to hurt ViaSat's profits in the short term.
Per the Zacks analyst, Mylan will remain under pressure as EpiPen sales decline due to competition and entry of generics. The CRL for generic Advair was also a huge setback given the market potential.
According to the Zacks analyst, CSRA's forecast of lower new business revenues as well as lower win rate will significantly hurt top-line growth in fiscal 2018.
Seasonality in demand and fast increasing R&D expenses at the Commercial Networks segment, in relation to ViaSat-3 payloads, are expected to hurt ViaSat's profits in the short term.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.